Design of an Expression System for Rapid Production of Tri-Functional Antibody Substitution of Hybrid Hybridoma Technology
Tri-functional antibodies, as an effective novel tumor targeting agents, are composed of anti-CD3 rat IgG2b and an anti-tumor antigen antibody. We have intended to develop a novel drug system to induce the apoptosis of HER2-expressing tumor cells, activate and engage cytotoxic T lymphocytes, natural killer cells, and macrophages. In addition, the drug can inhibit programmed death ligand 1 (PDL-1)-expressing tumor cells. We have designed a mammalian vector system suitable to express the trifunctional antibody composed of antiHER2×human-CD80: human-IgG1Fc antibody. This antibody contains four chains of anti-HER2/CL, anti-HER2/CH1-3, B7.1/CL, and B7.1/CH1-3 within the human IgG1 framework and so the vector system will simultaneously express the four chains. The amino acid/nucleotide sequences datasets were retrieved from the GenBank, UniProtKB and PDB databases. The heavy and light chains variable domain framework regions and complementarity determining regions of scA21 antibody were determined by IMGT/V-QUEST and Paratome software. The amino acid sequences of tri-functional antibody chains manually were assembled and converted to DNA sequences by sequence manipulation suite software. The adapting codon usage of these DNA sequences was performed by JCAT software. Finally, the secondary structures of obtained RNAs from the DNAs were individually analyzed by RNAfold program. The Prodigy equilibrium dissociation constant, a ratio of koff/kon, between the antibody and its antigen for hantiHER2VHCH-HER2, hantiHER2VLCL-HER2, CD80CH-CD28, and CD80CL-CD28 were equal to 3.60E-10, 3.10E-9, 1.10E-8 and 2.70E-10; respectively. These findings were confirmed the composition and nano-molar affinity of the respective constructs. A single specific no-cloning expression vector, pHuchiTriomAb, was designed in silico with a desirable length of 8.292 Kbps and bidirectional expression potential for the four chimeric antibody chains. This construct was designed, and gene codon usage adapted to be expressed within CHO cells and secreted a trifunctional antibody into the cell culture medium by interleukin 21 signal peptide.This robust expression system for rapid production of tri-functional antibody has been designed to substitute hybrid hybridoma technology (quadroma and trioma) with the facilitated purification of the trifunctional antibody from the antibody variants.
Scott A, Wolchok J, Old L. Antibody therapy of cancer. Nature Reviews Cancer. 2012;12(4):278-287.
Cho H, Mason K, Ramyar K, Stanley A, Gabelli S, Denney D et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756-760.
Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I et al. A novel ErbB2 epitope targeted by human antitumor immunoagents.FEBS Journal. 2011;278(7):1156-1166.
Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. New England Journal of Medicine. 2005;353(16):1659-1672.
Chelius D, Ruf P, Gruber P, Ploscher M, Liedtke R, Gansberger E et al. Structural and functional characterization of the trifunctional antibody catumaxomab. mAbs. 2010; 2(3):309-319.
Peach R, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A et al. Both Extracellular Immunoglobin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28.Journal of Biological Chemistry. 1995;270(36):21181-21187.
Homicsko K, Coukos G. Targeting Programmed Cell Death 1 in Ovarian Cancer. Journal of Clinical Oncology. 2015;33(34):3987-3989.
Brochet X, Lefranc M, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Research. 2008;36(Web Server):W503-W508.
Kunik V, Ashkenazi S, Ofran Y. Paratome: an online tool for systematic identification of antigen-binding regions in antibodies based on sequence or structure. Nucleic Acids Research. 2012;40(W1):W521-W524.
Grote A, Hiller K, Scheer M, Munch R, Nortemann B, Hempel D et al. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Research. 2005;33(Web Server):W526-W531.
Hofacker I. Vienna RNA secondary structure server. Nucleic Acids Research. 2003;31(13):3429-3431.
|Issue||Vol 56, No 3 (2018)|
|Insilico Tri-functional antibody Cancer Immunotherapy Biotechnology|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|